Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1989 Aug;29(4):231–236. doi: 10.1007/BF00199209

Chemoimmunotherapy with cyclophosphamide and bestatin in experimental metastasis in mice

Fuminori Abe 1,✉, Mark Schneider 2, Paul L Black 3, James E Talmadge 2
PMCID: PMC11039019  PMID: 2752391

Abstract

Bestatin has significant therapeutic activity (even following oral administration) for the treatment of metastatic disease, an activity which is limited by tumor burden. Therefore, the therapeutic potential of bestatin was examined in combination with chemotherapy to determine if there is additive activity for heavy tumor burdens. Bestatin significantly increased therapeutic activity and decreased the myelotoxicity of cyclophosphamide following a single injection of cyclophosphamide or split daily doses. In immune function studies, in tumor-bearing antimals, bestatin increased the number of colony-forming units (granulocyte-macrophage) (CFU) and alveolar macrophage tumoricidal activity. However, when bestatin was combined with cyclophosphamide, which depressed bone marrow and macrophage activity, it did not show apparent augmentation of macrophage and NK cell activity, but did significantly increase bone marrow CFU activity. Thus, in combined chemoimmunotherapy, bestatin appears to enhance therapeutic activity by accelerating the recovery of hematopoiesis. We suggest, therefore, that a combination chemotherapy protocol, with oral bestatin, may facilitate myelorestoration following aggressive chemotherapy. The majority of biological response modifiers require parental administration; thus, the identification of an orally active, synthetic immunoaugmenting agent with a defined receptor is of particular interest.

Keywords: Cyclophosphamide, Tumor Burden, Therapeutic Activity, Experimental Metastasis, Bestatin

Footnotes

This research was sponsored by the National Cancer Institute, DHHS, under contract no. N01-23910 with Program Resources Inc. The contents of this publication do not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

References

  • 1.Abe F, Shibuya K, Uchida M, Takahashi K, Horinishi H, Matsuda A, Ishizuka M, Takeuchi T, Umezawa H. Effect of bestatin on syngeneic tumors in mice. Gann. 1984;75:89. [PubMed] [Google Scholar]
  • 2.Abe F, Shibuya K, Ashizawa J, Takahashi K, Horinishi H, Matsuda A, Ishizuka M, Takeuchi T, Umezawa H. Enhancement of antitumor effect of cytotoxic agents by bestatin. J Antibiot. 1985;38:411. doi: 10.7164/antibiotics.38.411. [DOI] [PubMed] [Google Scholar]
  • 3.Abe F, Shibuya K, Ashizawa J, Takahashi K, Horinishi H, Matsuda A, Ishizuka M, Takeuchi T, Umezawa H. Enhancement of antitumor effect of cytotoxic agents by bestatin. J Antibiot. 1985;38:411. doi: 10.7164/antibiotics.38.411. [DOI] [PubMed] [Google Scholar]
  • 4.Abe F, Hayashi M, Horinishi H, Matsuda A, Ishizuka M, Umezawa H. Enhancement of graft-versus-host reaction and delayed cutaneous hypersensitivity in mice by ubenimex. J Antibiot. 1986;39:1172. doi: 10.7164/antibiotics.39.1172. [DOI] [PubMed] [Google Scholar]
  • 5.Abe F, Alvord G, Koyama M, Matsuda A, Talmadge JE. Optimal therapeutic protocol and pharmacokinetics of bestatin treatment against experimental metastases. Cancer Immunol Immunother. 1989;28:29–33. doi: 10.1007/BF00205797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Blomgren H, Edsmyr F, Esposti P-L, Näslund I. Immunological and hematological monitoring in bladder cancer patients receiving adjuvant bestatin treatment following radiation therapy. A prospective randomized trail. Biomed Pharmacother. 1984;38:143. [PubMed] [Google Scholar]
  • 7.Blomgren H, Näslund I, Esposti P-L, Johansen L, Aaskoven O. Adjuvant bestatin immunotherapy in patients with transitional cell carcinoma of the bladder. Cancer Immunol Immunother. 1987;25:40. doi: 10.1007/BF00199299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Bryley-Rosset M, Florentin L, Kiger N, Schulz J, Mathe G. Restoration of impaired immune functions of aged animals by chronic bestatin treatment. Immunology. 1984;38:75. [PMC free article] [PubMed] [Google Scholar]
  • 9.Castelli MP, Black PL, Schneider M, Pennington R, Abe F, Talmadge JE. Protective, restorative and therapeutic properties of recombinant human Il-1 in rodent models. J Immunol. 1988;140:3830. [PubMed] [Google Scholar]
  • 10.Ebihara K, Abe F, Yamashita T, Shibuya K, Hayashi E, Takahashi K, Horinishi H, Enomoto M, Ishizuka M, Umezawa H. The effect of ubenimex on N-methyl-N'-nitro-N'-nitrosoguanidine-induced stomach tumor in rats. J Antibiot. 1986;39:955. doi: 10.7164/antibiotics.39.966. [DOI] [PubMed] [Google Scholar]
  • 11.Hart IR. The selection and characterization of an/invasive variant of the B16 melanoma. Am J Pathol. 1979;97:587. [PMC free article] [PubMed] [Google Scholar]
  • 12.Ishizuka M, Masuda T, Kanbayashi N, Fukazawa S, Takeuchi T, Ayoyagi T, Umezawa H. Effect of bestatin on mouse immune system and experimental murine tumors. J Antibiot. 1980;33:642. doi: 10.7164/antibiotics.33.642. [DOI] [PubMed] [Google Scholar]
  • 13.Ishizuka M, Masuda T, Mizutani S, Takeuchi T, Umezawa H. Antitumor cells found in tumor-bearing mice given ubenimex. J Antibiot. 1987;40:697. doi: 10.7164/antibiotics.40.697. [DOI] [PubMed] [Google Scholar]
  • 14.Kaya G, Akin C, Altug T, Devrim S. The antitumor effect of bleomycin combined with bestatin against Ehrlich ascites carcinoma in mice (42667) Proc Soc Exp Biol Med. 1988;187:292. doi: 10.3181/00379727-187-42667. [DOI] [PubMed] [Google Scholar]
  • 15.Kuramochi H, Motegi A, Iwabuchi M, Takahashi K, Horinishi H, Umezawa H. Action of ubenimex on aminopeptidase activities in spleen cells and peritoneal macrophages from mice. J Antibiot. 1987;40:1605. doi: 10.7164/antibiotics.40.1605. [DOI] [PubMed] [Google Scholar]
  • 16.Kurita S, Ota K, Yamada K, Masakoa T, Uzuka Y, Ogawa N. Immunotherapy with bestatin for acute non-lymphocytic leukemia (ANLL) in adults. Jpn J Cancer Chemother. 1984;11(12):2442. [PubMed] [Google Scholar]
  • 17.Leyhausen G, Gramzow M, Zahn RK, Steffen R, Umezawa H, Müller WEG. Immunochemical identification of the cell surface bound leucine aminopeptidase, the target enzyme for the immunostimulant bestatin. J Antibiot. 1983;36:728. doi: 10.7164/antibiotics.36.728. [DOI] [PubMed] [Google Scholar]
  • 18.Leyhausen G, Schuster DK, Vaith P, Zahn RK, Umezawa H, Falke D, Müller WEG. Identification and properties of the cell membrane bound leucine aminopeptidase interacting with the potential immunostimulant and chemotherapeutic agent bestatin. Biochem Pharmacol. 1983;32:1051. doi: 10.1016/0006-2952(83)90624-x. [DOI] [PubMed] [Google Scholar]
  • 19.Reference deleted
  • 20.Makinen KK, Oksala E. Evidence on the involvement in inflammation of an enzyme resembling aminopeptidase B. Clin Chim Acta. 1973;49:301. doi: 10.1016/0009-8981(73)90226-x. [DOI] [PubMed] [Google Scholar]
  • 21.Morahan PS, Edelson PJ, Gass K. Changes in macrophages ectoenzymes associated with antitumor activity. J Immunol. 1980;125:1312. [PubMed] [Google Scholar]
  • 22.Müller WEG, Schuster DK, Zahn RK, Maidhof A, Leyhausen G, Falke D, Koren R, Umezawa H. Properties and specificity of binding sites for the immunodulater bestatin on the surface of mammalian cells. Int J Immunopharmacol. 1982;4:393. doi: 10.1016/0192-0561(82)90012-1. [DOI] [PubMed] [Google Scholar]
  • 23.Nagaoka I, Yamashita T. Inactivation of phagocytosis-stimulating activity of tuftsin by polymorphonuclear neutrophils. A possible role of leucine aminopeptidase as an ectoenzyme. Biochim Biophys Acta. 1981;675:85. doi: 10.1016/0304-4165(81)90072-6. [DOI] [PubMed] [Google Scholar]
  • 24.Nishizawa R, Saino T, Suzuki M, Fujii T, Shirai T, Aoyagi T, Umezawa H. A facile synthesis of bestatin. J Antibiot. 1983;36:695. doi: 10.7164/antibiotics.36.695. [DOI] [PubMed] [Google Scholar]
  • 25.Ota K, Kurita S, Yamada K, Masaoka T, Uzuka Y, Ogawa N. Results of investigation into prognosis after immunotherapy with bestatin for acute nonlymphocytic leukemia in adults. Jpn J Cancer Chemother. 1986;13:1017. [PubMed] [Google Scholar]
  • 26.Schorlemmer HU, Bosslet K, Dickneite G, Luben G, Sedlacek HH. Studies on the mechanism of action of the immunomodulator bestatin in various screening test systems. Behring Inst Mitt. 1984;74:157. [PubMed] [Google Scholar]
  • 27.Shibuya K, Hayashi E, Abe F, Takahashi K, Horinishi H, Ishizuka M, Takeuchi T, Umezawa H. Enhancement of interleukin 1 and interleukin 2 release by ubenimex. J Antibiot. 1987;40:363. doi: 10.7164/antibiotics.40.363. [DOI] [PubMed] [Google Scholar]
  • 28.Soderling E, Knuuttila M. Release of the chloride-dependent arginine aminopeptidase from PMN leukocytes and macrophages during phagocytosis. Life Sci. 1980;26:303. doi: 10.1016/0024-3205(80)90342-2. [DOI] [PubMed] [Google Scholar]
  • 29.Suda H, Aoyagi T, Takeuchi T, Umezawa H. Inhibition of aminopeptidase B and leucine aminopeptidase by bestatin and its stereoisomer. Arch Biochem Biophys. 1976;177:196. doi: 10.1016/0003-9861(76)90429-x. [DOI] [PubMed] [Google Scholar]
  • 30.Suda H, Takita T, Aoyagi T, Umezawa H. The structure of bestatin. J Antibiot. 1976;29:100. doi: 10.7164/antibiotics.29.100. [DOI] [PubMed] [Google Scholar]
  • 31.Talmadge JE. Recent results of bestatin, 1985. Tokyo: Jpn Antibiot Res Assoc; 1985. Immunomodulatory and therapeutic characteristics of bestatin; p. 55. [Google Scholar]
  • 32.Talmadge JE, Lenz BF, Pennington R, Long C, Phillips H, Schneider M, Tribble H. Immunomodulatory and therapeutic properties of bestatin in mice. Cancer Res. 1986;46:4505. [PubMed] [Google Scholar]
  • 33.Talmadge JE, Koyama M, Matsuda A, Long C, Abe F. recent results of bestatin, 1986. Tokyo: Jpn Antibiot Res Assoc; 1987. Immunotherapeutic properties of bestatin: mechanism of activity; p. 8. [Google Scholar]
  • 34.Tsuruo T, Naganuma K, Iida H, Yamori T, Tsukagoshi S, Sakurai Y. Inhibition of lymph node metastasis of P388 leukemia by bestatin in mice. J Antibiot. 1981;34:1206. doi: 10.7164/antibiotics.34.1206. [DOI] [PubMed] [Google Scholar]
  • 35.Umezawa H, Aoyagi T, Suda H, Hammda M, Takeuchi T. Bestatin, an inhibitor of aminopeptidase B, produced by actinomycete. J Antibiot. 1976;29:97. doi: 10.7164/antibiotics.29.97. [DOI] [PubMed] [Google Scholar]
  • 36.Umezawa H, Ishizuka M, Aoyagi T, Takeuchi T. Enhancement of delayed-type hypersensitivity by bestatin, an inhibitor of aminopeptidase B and leucine aminopeptidase. J Antibiot. 1976;29:857. doi: 10.7164/antibiotics.29.857. [DOI] [PubMed] [Google Scholar]
  • 37.Wachsmuth ED. Aminopeptidase as a marker for macrophage differentiation. Exp Cell Res. 1975;96:409. doi: 10.1016/0014-4827(75)90275-x. [DOI] [PubMed] [Google Scholar]
  • 38.Yamakura Y, Shimbo T, Yata J. Small molecular immunomodifiers of microbial origin. New York: Pergamon Press; 1981. Effect of an aminopeptidase inhibitor (bestatin) on human lymphocytes. I. Effect on pokeweed mitogen-induced in vitro immunoglobulin production; p. 109. [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES